{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"INCB001158 was dosed orally BID.","groups":[{"description":"INCB001158 administered orally in patients at 50, 75, and 100 mg doses BID with advanced/metastatic solid tumors in combination with pembrolizumab (200 mg IV Q3W)","id":"OG000","title":"INCB001158 as Combination Therapy at 50, 75, and 100 mg BID"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"RP2D of INCB001158 in Combination With Pembrolizumab","type":"SECONDARY","unitOfMeasure":"milligrams"}